FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Eisai sedative not approvable

A sedative Eisai gained through its acquisition of MGI Pharma has been hit with a ‘not approvable' letter from the FDA. But the pharma company says it strongly believes that further talks with the agency will lead to an approval for fospropofol disodium, which was endorsed by an FDA expert committee, with the caveat that it would like to see more data on the drug's potential impact on the obese and elderly. Release | Story

More stories about fospropofol disodium   FDA rejection   MGI Pharma   Eisai  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 11 + 9?
To combat spam, please solve the math question above.